CONFORMED
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 3, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822
25-1229323
(State of other jurisdiction (Commission File
Number) (IRS Employer
of incorporation)
Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On February 3, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that in-home testing of the Diasensor
1000 noninvasive glucose sensor for diabetics began today. The
study is anticipated to take approximately 120 days to complete.
Upon completion of the study, the Company will resubmit its
510(k) Notification ,with the new data, to the FDA for approval
to market the Diasensor 1000 in the United States.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 3, 1997
BICO
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Bldg. 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL BEGINS IN-HOME TESTING OF DIASENSOR 1000
Pittsburgh, PA - February 3, 1997 - Biocontrol Technology,
Inc. (Nasdaq:BICO) announced today that in-home testing of the
Diasensor 1000 noninvasive glucose sensor for diabetics began
today.
Although there can be no guarantees, the study which was
requested by the Food and Drug Administration (FDA) is
anticipated to take approximately 120 days to complete. Following
completion of the study, the Company will resubmit its 510(k)
Notification, with the new data, to the FDA for approval to
market the Diasensor 1000 in the United States.
The Company also stated that further details of the in-home
study will remain confidential at this time.
Without the need to finger prick, as current monitors
require, the Diasensor 1000 measures blood glucose levels using
near infrared technology.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
